Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775
Yonemori, Kan, Yunokawa, Mayu, Ushijima, Kimio, Sakata, Jun, Shikama, Ayumi, Minobe, Shinichiro, Usami, Tomoka, Enomoto, Takayuki, Takehara, Kazuhiro, Hasegawa, Kosei, Yamagami, Wataru, Yamamoto, Keiko, Han, Shirong, Dutta, Lea, Orlowski, Robert, Miura, Takuma, Makker, Vicky, Fujiwara, Keiichi
Published in Cancer science (01.10.2022)
Published in Cancer science (01.10.2022)
Get full text
Journal Article
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E., Kopyltsov, Evgeny, Méndez-Vidal, María J., Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R., Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C., Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E., Smith, Alan D., Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F., Xing, Dongyuan, Choueiri, Toni K.
Published in The New England journal of medicine (08.04.2021)
Published in The New England journal of medicine (08.04.2021)
Get full text
Journal Article
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146
Makker, Vicky, Taylor, Matthew H, Aghajanian, Carol, Cohn, Allen L, Brose, Marcia S, Simone, Christopher Di, Cao, Zhu Alexander, Suttner, Leah, Loboda, Andrey, Cristescu, Razvan, Jelinic, Petar, Orlowski, Robert, Dutta, Lea, Matsui, Junji, Dutcus, Corina E, Minoshima, Yukinori, Messing, Mark J
Published in Journal for immunotherapy of cancer (19.01.2024)
Published in Journal for immunotherapy of cancer (19.01.2024)
Get full text
Journal Article
354 Lenvatinib and pembrolizumab in advanced endometrial carcinoma (EC): long-term efficacy and safety update from a phase 1b/2 study
Makker, Vicky, Aghajanian, Carol, Cohn, Allen, Romeo, Margarita, Bratos, Raquel, Brose, Marcia, Messing, Mark, Dutta, Lea, Dutcus, Corina, Huang, Jie, Schmidt, Emmett, Orlowski, Robert, Taylor, Matthew
Published in Journal for immunotherapy of cancer (01.11.2021)
Published in Journal for immunotherapy of cancer (01.11.2021)
Get full text
Journal Article
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K
Published in The New England journal of medicine (08.04.2021)
Published in The New England journal of medicine (08.04.2021)
Get full text
Journal Article
Web Resource
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer
Makker, Vicky, Colombo, Nicoletta, Casado Herráez, Antonio, Santin, Alessandro D, Colomba, Emeline, Miller, David S, Fujiwara, Keiichi, Pignata, Sandro, Baron-Hay, Sally, Ray-Coquard, Isabelle, Shapira-Frommer, Ronnie, Ushijima, Kimio, Sakata, Jun, Yonemori, Kan, Kim, Yong Man, Guerra, Eva M, Sanli, Ulus A, McCormack, Mary M, Smith, Alan D, Keefe, Stephen, Bird, Steven, Dutta, Lea, Orlowski, Robert J, Lorusso, Domenica
Published in The New England journal of medicine (03.02.2022)
Published in The New England journal of medicine (03.02.2022)
Get full text
Journal Article
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study
Gaspar, Nathalie, Venkatramani, Rajkumar, Hecker-Nolting, Stefanie, Melcon, Soledad Gallego, Locatelli, Franco, Bautista, Francisco, Longhi, Alessandra, Lervat, Cyril, Entz-Werle, Natacha, Casanova, Michela, Aerts, Isabelle, Strauss, Sandra J, Thebaud, Estelle, Morland, Bruce, Nieto, Adela Cañete, Marec-Berard, Perrine, Gambart, Marion, Rossig, Claudia, Okpara, Chinyere E, He, Cixin, Dutta, Lea, Campbell-Hewson, Quentin
Published in The lancet oncology (01.09.2021)
Published in The lancet oncology (01.09.2021)
Get full text
Journal Article
Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
Makker, Vicky, Taylor, Matthew H., Oaknin, Ana, Casado Herraez, Antonio, Orlowski, Robert, Dutta, Lea, Ren, Min, Zale, Melissa, O'Malley, David M.
Published in The oncologist (Dayton, Ohio) (01.09.2021)
Published in The oncologist (Dayton, Ohio) (01.09.2021)
Get full text
Journal Article
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update
Makker, Vicky, Aghajanian, Carol, Cohn, Allen L, Romeo, Margarita, Bratos, Raquel, Brose, Marcia S, Messing, Mark, Dutta, Lea, Dutcus, Corina E, Huang, Jie, Schmidt, Emmett V, Orlowski, Robert, Taylor, Matthew H
Published in Journal of clinical oncology (10.02.2023)
Published in Journal of clinical oncology (10.02.2023)
Get full text
Journal Article
Analysis of tumor biomarkers in patients (pts) with advanced hepatocellular carcinoma (HCC) from a phase 1b study of E7386, a CREB-binding protein/β-catenin interaction inhibitor, in combination with lenvatinib
Kudo, Masatoshi, Kato, Naoya, Kondo, Shunsuke, Inaba, Yoshitaka, Ueshima, Kazuomi, Sasaki, Mitsuhito, Ogasawara, Sadahisa, Sahara, Takatoshi, Li, Shuyu D, Shen, Jialing, Kimura, Takayuki, Dutta, Lea, Tamai, Toshiyuki, Ikeda, Masafumi
Published in Journal of clinical oncology (20.01.2024)
Published in Journal of clinical oncology (20.01.2024)
Get full text
Journal Article
Dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC) and other solid tumors including endometrial cancer (EC)
Lee, Jung-Yun, Ryoo, Baek-Yeol, Kim, Jin Won, Cheng, Ann-Lii, Finn, Richard S., Hasegawa, Kosei, Makker, Vicky, Kudo, Masatoshi, Miller, David Scott, Merle, Philippe, Ulahannan, Susanna Varkey, Hosaka, Tetsuya, Sahara, Takatoshi, He, Cixin S., O'Hara, Karen, Dutta, Lea, Tamai, Toshiyuki, Ikeda, Masafumi
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer
Makker, Vicky, Casado Herraez, Antonio, Aghajanian, Carol, Fujiwara, Keiichi, Pignata, Sandro, Penson, Richard T., Dutcus, Corina E., Guo, Matthew, Dutta, Lea, Orlowski, Robert, Smith, Alan, Miller, David S.
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Association between biomarkers and clinical outcomes of lenvatinib + pembrolizumab in advanced renal cell carcinoma (RCC): Results from Study 111/KEYNOTE-146
Lee, Chung-Han, Rasco, Drew W., Rao, Arpit, Taylor, Matthew H., Hsieh, James J, Pinto, Alvaro, Vogelzang, Nicholas J., Cao, Z. Alexander, Suttner, Leah, Loboda, Andrey, Vajdi, Amir, Predoiu, Raluca Andreia, Nebozhyn, Michael, Lunceford, Jared, Perini, Rodolfo F., Matsui, Junji, Minoshima, Yukinori, Dutcus, Corina E., Dutta, Lea, Motzer, Robert J.
Published in Journal of clinical oncology (20.02.2022)
Published in Journal of clinical oncology (20.02.2022)
Get full text
Journal Article
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
Grünwald, Viktor, Powles, Thomas, Choueiri, Toni K, Hutson, Thomas E, Porta, Camillo, Eto, Masatoshi, Sternberg, Cora N, Rha, Sun Young, He, Cixin S, Dutcus, Corina E, Smith, Alan, Dutta, Lea, Mody, Kalgi, Motzer, Robert J
Published in Future oncology (London, England) (01.03.2019)
Published in Future oncology (London, England) (01.03.2019)
Get full text
Journal Article
ENGOT-en9/LEAP-001: A phase III study of first-line pembrolizumab plus lenvatinib versus chemotherapy in advanced or recurrent endometrial cancer
Marth, Christian, Vulsteke, Christof, Rubio Pérez, Maria Jesus, Makker, Vicky, Braicu, Elena Ioana, McNeish, Iain A., Madry, Radoslaw, Ayhan, Ali, Hasegawa, Kosei, Wu, Xiaohua, Dutta, Lea, Xu, Cindy, Keefe, Stephen Michael, Lee, John J., Pignata, Sandro
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC)
Lorusso, Domenica, Colombo, Nicoletta, Casado Herraez, Antonio, Santin, Alessandro, Colomba, Emeline, Miller, David Scott, Fujiwara, Keiichi, Pignata, Sandro, Baron-Hay, Sally E., Ray-Coquard, Isabelle Laure, Shapira-Frommer, Ronnie, Kim, Yong Man, McCormack, Mary, Bird, Steven, Prabhu, Vimalanand S., Martin Nguyen, Allison, Zhao, Qi, Dutta, Lea, Makker, Vicky
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms
Hutson, Thomas E., Choueiri, Toni K., Motzer, Robert J., Rha, Sun Young, Alyasova, Anna, Merchan, Jaime R., Gurney, Howard, Peer, Avivit, Takagi, Toshio, Porta, Camillo, Powles, Thomas, Grünwald, Viktor, De Giorgi, Ugo, Vaishampayan, Ulka N., Schmidinger, Manuela, Glen, Hilary, Rodriguez-Lopez, Karla, Xing, Dongyuan, Dutta, Lea, Eto, Masatoshi
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer
Makker, Vicky, Colombo, Nicoletta, Herráez, Antonio Casado, Santin, Alessandro, Colomba, Emeline, Miller, David, Fujiwara, Keiichi, Pignata, Sandro, Baron-Hay, Sally, Ray-Coquard, Isabelle, Shapira-Frommer, Ronnie, Ushijima, Kimio, Sakata, Jun, Yonemori, Kan, Kim, Yong Man, Guerra, Eva, Sanli, Ulus, McCormack, Mary, Huang, Jie, Smith, Alan, Keefe, Stephen, Dutta, Lea, Orlowski, Robert, Lorusso, Domenica
Published in Gynecologic oncology (01.08.2021)
Published in Gynecologic oncology (01.08.2021)
Get full text
Journal Article
A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma
Motzer, Robert J., Grünwald, Viktor, Hutson, Thomas E., Porta, Camillo, Powles, Thomas, Eto, Masatoshi, Dutcus, Corina E., Baig, Mahadi Ali, Dutta, Lea, Li, Di, Choueiri, Toni K.
Published in Journal of clinical oncology (20.02.2018)
Published in Journal of clinical oncology (20.02.2018)
Get full text
Journal Article
Lenvatinib (LEN) plus pembrolizumab (PEMBRO) for early-line treatment of advanced/recurrent endometrial cancer (EC)
Makker, Vicky, Taylor, Matthew H., Aghajanian, Carol, Oaknin, Ana, Mier, James, Cohn, Allen Lee, Romeo, Margarita, Bratos, Raquel, Brose, Marcia S., DiSimone, Christopher, Messing, Mark, Dutta, Lea, Ren, Min, Schmidt, Emmett V., Orlowski, Robert, McKenzie, Jodi Alicia, Gillis, Kathryn, Casado Herraez, Antonio
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article